• Something wrong with this record ?

Antimicrobial Peptides for Topical Treatment of Osteomyelitis and Implant-Related Infections: Study in the Spongy Bone

P. Melicherčík, O. Nešuta, V. Čeřovský,

. 2018 ; 11 (1) : . [pub] 20180216

Language English Country Switzerland

Document type Journal Article

Grant support
NV16-27726A MZ0 CEP Register

We examined the benefits of short linear α-helical antimicrobial peptides (AMPs) invented in our laboratory for treating bone infection and preventing microbial biofilm formation on model implants due to causative microorganisms of osteomyelitis. For this purpose, we introduced a model of induced osteomyelitis that utilizes human femur heads obtained from the hospital after their replacement with artificial prostheses. We found that the focus of the infection set up in the spongy part of this bone treated with AMP-loaded calcium phosphate cement was eradicated much more effectively than was the focus treated with antibiotics such as vancomycin or gentamicin loaded into the same cement. This contradicts the minimum inhibitory concentrations (MIC) values of AMPs and antibiotics against some bacterial strains obtained in standard in vitro assays. The formation of microbial biofilm on implants made from poly(methylmethacrylate)-based bone cement loaded with AMP was evaluated after the implants' removal from the infected bone sample. AMPs loaded in such model implants prevented microbial adhesion and subsequent formation of bacterial biofilm on their surface. Biofilms did form, on the other hand, on control implants made from the plain cement when these were implanted into the same infected bone sample. These results of the experiments performed in human bone tissue highlight the clinical potential of antimicrobial peptides for use in treating and preventing osteomyelitis caused by resistant pathogens.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18009991
003      
CZ-PrNML
005      
20180404131300.0
007      
ta
008      
180404s2018 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/ph11010020 $2 doi
035    __
$a (PubMed)29462909
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Melicherčík, Pavel $u Department of Orthopaedics, First Faculty of Medicine, Charles University in Prague and University Hospital in Motol, V Úvalu 84, 150 06 Prague 5, Czech Republic. Pavel.Melichercik@fnmotol.cz.
245    10
$a Antimicrobial Peptides for Topical Treatment of Osteomyelitis and Implant-Related Infections: Study in the Spongy Bone / $c P. Melicherčík, O. Nešuta, V. Čeřovský,
520    9_
$a We examined the benefits of short linear α-helical antimicrobial peptides (AMPs) invented in our laboratory for treating bone infection and preventing microbial biofilm formation on model implants due to causative microorganisms of osteomyelitis. For this purpose, we introduced a model of induced osteomyelitis that utilizes human femur heads obtained from the hospital after their replacement with artificial prostheses. We found that the focus of the infection set up in the spongy part of this bone treated with AMP-loaded calcium phosphate cement was eradicated much more effectively than was the focus treated with antibiotics such as vancomycin or gentamicin loaded into the same cement. This contradicts the minimum inhibitory concentrations (MIC) values of AMPs and antibiotics against some bacterial strains obtained in standard in vitro assays. The formation of microbial biofilm on implants made from poly(methylmethacrylate)-based bone cement loaded with AMP was evaluated after the implants' removal from the infected bone sample. AMPs loaded in such model implants prevented microbial adhesion and subsequent formation of bacterial biofilm on their surface. Biofilms did form, on the other hand, on control implants made from the plain cement when these were implanted into the same infected bone sample. These results of the experiments performed in human bone tissue highlight the clinical potential of antimicrobial peptides for use in treating and preventing osteomyelitis caused by resistant pathogens.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Nešuta, Ondřej $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo nám. 2, 166 10 Prague 6, Czech Republic. nesuta@uochb.cas.cz.
700    1_
$a Čeřovský, Václav $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo nám. 2, 166 10 Prague 6, Czech Republic. cerovsky@uochb.cas.cz.
773    0_
$w MED00184066 $t Pharmaceuticals $x 1424-8247 $g Roč. 11, č. 1 (2018)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29462909 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180404 $b ABA008
991    __
$a 20180404131339 $b ABA008
999    __
$a ind $b bmc $g 1287476 $s 1006803
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 11 $c 1 $e 20180216 $i 1424-8247 $m Pharmaceuticals $n Pharmaceuticals (Basel) $x MED00184066
GRA    __
$a NV16-27726A $p MZ0
LZP    __
$a Pubmed-20180404

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...